BofA downgraded Bristol Myers to Neutral from Buy with a price target of $60, down from $68.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMY:
- Edgewise shares still reflect limited credit for EDG-7500, says Wedbush
- RayzeBio downgraded to Neutral from Overweight at JPMorgan
- Karuna Therapeutics downgraded to Neutral from Overweight at JPMorgan
- Here’s Why Cytokinetics (NASDAQ:CYTK) Stock Surged Yesterday
- RayzeBio downgraded to Hold from Buy at Truist